Drug intelligence / Profile preview

E2022

Development stage: Phase 1
Administration: Transdermal

Overview

E2022 is an investigational drug studied in a patch (tape) formulation, with clinical research focused on evaluating its safety and pharmacokinetics. The available information indicates that it has been tested in a Phase 1 comparative study to assess different patch formulations, but specific details about its mechanism of action, therapeutic target, or primary indication are not provided in the accessible sources. No further data regarding its molecular class or disease focus is available from current public records[1].

Beyond the preview

Go deeper on E2022.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on E2022.

Explore the full profile